ClinicalTrials.gg

Program

CS5007

A development code.

Its studies are led by CStone Pharmaceuticals.

Furthest: phase 1, since May 28, 20261 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CStone Pharmaceuticals11 open or runningphase 1since May 28, 2026May 28, 2026Jan 2028phase 1 · NCT07622524

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2026First study: phase 1 study in Advanced Solid TumorsFirst studyNCT07622524 · 310 planned · Australia, China

Ahead

  1. Jan 2028Primary completion: phase 1 study in Advanced Solid TumorsNCT07622524

TargetBeta

EGFR →ERBB3 →read by rule
“A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti Tumor Activities of CS5007, a Novel EGFR and HER3 Bispecific Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07622524Advanced Solid Tumors · Australia, China1RecruitingJan 2028310

How it is read

Names in the registry

  • “CS5007”, 1 entry

Codes read as this program: CS5007.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.